I 
115TH CONGRESS 
2D SESSION 
H. R. 5554 
To amend the Federal Food, Drug, and Cosmetic Act to reauthorize user 
fee programs relating to new animal drugs and generic new animal drugs. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 18, 2018 
Mr. MULLIN (for himself, Mr. SCHRADER, Mr. WALDEN, Mr. PALLONE, Mr. 
BURGESS, and Mr. GENE GREEN of Texas) introduced the following bill; 
which was referred to the Committee on Energy and Commerce 
A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
reauthorize user fee programs relating to new animal 
drugs and generic new animal drugs. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Animal Drug and Ani-
mal Generic Drug User Fee Amendments of 2018’’. 
SEC. 2. TABLE OF CONTENTS; REFERENCES IN ACT. 
(a) TABLE OF CONTENTS.—The table of contents for 
this Act is as follows: 
Sec. 1. Short title. 
Sec. 2. Table of contents; references in Act. 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6211
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
TITLE I—FEES RELATING TO ANIMAL DRUGS 
Sec. 101. Short title; finding. 
Sec. 102. Definitions. 
Sec. 103. Authority to assess and use animal drug fees. 
Sec. 104. Reauthorization; reporting requirements. 
Sec. 105. Savings clause. 
Sec. 106. Effective date. 
Sec. 107. Sunset dates. 
TITLE II—FEES RELATING TO GENERIC ANIMAL DRUGS 
Sec. 201. Short title; finding. 
Sec. 202. Authority to assess and use generic new animal drug fees. 
Sec. 203. Reauthorization; reporting requirements. 
Sec. 204. Savings clause. 
Sec. 205. Effective date. 
Sec. 206. Sunset dates. 
TITLE III—MISCELLANEOUS PROVISIONS 
Sec. 301. Electronic submissions. 
Sec. 302. Index of legally marketed unapproved new animal drugs for minor 
species. 
Sec. 303. Misbranded drugs and devices. 
(b) REFERENCES IN ACT.—Except as otherwise spec-
ified, amendments made by this Act to a section or other 
provision of law are amendments to such section or other 
provision of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 301 et seq.). 
TITLE I—FEES RELATING TO 
ANIMAL DRUGS 
SEC. 101. SHORT TITLE; FINDING. 
(a) SHORT TITLE.—This title may be cited as the 
‘‘Animal Drug User Fee Amendments of 2018’’. 
(b) FINDING.—Congress finds that the fees author-
ized by the amendments made in this title will be dedi-
cated toward expediting the animal drug development 
process and the review of new and supplemental animal 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
drug applications and investigational animal drug submis-
sions as set forth in the goals identified for purposes of 
part 4 of subchapter C of chapter VII of the Federal Food, 
Drug, and Cosmetic Act, in the letters from the Secretary 
of Health and Human Services to the Chairman of the 
Committee on Energy and Commerce of the House of 
Representatives and the Chairman of the Committee on 
Health, Education, Labor, and Pensions of the Senate as 
set forth in the Congressional Record. 
SEC. 102. DEFINITIONS. 
Section 739 (21 U.S.C. 379j–11) is amended— 
(1) by amending paragraph (1) to read as fol-
lows: 
‘‘(1)(A) The term ‘animal drug application’ 
means— 
‘‘(i) an application for approval of any new 
animal drug submitted under section 512(b)(1); 
or 
‘‘(ii) an application for conditional ap-
proval of a new animal drug submitted under 
section 571. 
‘‘(B) Such term does not include either a new 
animal drug application submitted under section 
512(b)(2) or a supplemental animal drug applica-
tion.’’; and 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
(2) in paragraph (8), by adding at the end the 
following: 
‘‘(I) The activities necessary for implemen-
tation of the United States and European 
Union Good Manufacturing Practice Mutual In-
spection Agreement with respect to animal drug 
products subject to review, including implemen-
tation activities prior to and following product 
approval.’’. 
SEC. 103. AUTHORITY TO ASSESS AND USE ANIMAL DRUG 
FEES. 
(a) FEE REVENUE AMOUNTS.—Section 740(b) (21 
U.S.C. 379j–12(b)) is amended— 
(1) in paragraph (1)— 
(A) in subparagraph (A)— 
(i) by striking ‘‘2014’’ and inserting 
‘‘2019’’; and 
(ii) by striking ‘‘$23,600,000’’ and in-
serting ‘‘$30,331,240’’; and 
(B) in subparagraph (B)— 
(i) by striking ‘‘2015 through 2018’’ 
and inserting ‘‘2020 through 2023’’; and 
(ii) by striking ‘‘$21,600,000’’ and in-
serting ‘‘$29,931,240’’; and 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
(2) in paragraph (2), in the matter preceding 
subparagraph (A), by striking ‘‘determined’’ and in-
serting ‘‘established’’. 
(b) ANNUAL FEE SETTING; ADJUSTMENTS.— 
(1) 
INFLATION
ADJUSTMENT.—Section 
740(c)(2) (21 U.S.C. 379j–12(c)(2)) is amended— 
(A) in the matter preceding subparagraph 
(A)— 
(i) by striking ‘‘For fiscal year 2015’’ 
and inserting ‘‘(A) For fiscal year 2020’’; 
and 
(ii) by inserting ‘‘multiplying such 
revenue amounts by’’ before ‘‘an amount’’; 
(B) by redesignating subparagraphs (A), 
(B), and (C) as clauses (i), (ii), and (iii), re-
spectively; 
(C) by striking the flush text at the end; 
and 
(D) by adding at the end the following new 
subparagraph: 
‘‘(B) COMPOUNDED
BASIS.—The adjustment 
made each fiscal year after fiscal year 2020 under 
this paragraph shall be applied on a compounded 
basis to the revenue amount calculated under this 
paragraph for the most recent previous fiscal year.’’. 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
(2) WORKLOAD ADJUSTMENTS.—Paragraph (3) 
of section 740(c) (21 U.S.C. 379j–12(c)) is amended 
to read as follows: 
‘‘(3) WORKLOAD ADJUSTMENTS.— 
‘‘(A) IN GENERAL.—For fiscal year 2020 
and subsequent fiscal years, after the fee rev-
enue amounts established under subsection (b) 
are adjusted for inflation in accordance with 
paragraph (2), the fee revenue amounts shall be 
further adjusted for such fiscal year to reflect 
changes in the workload of the Secretary for 
the process for the review of animal drug appli-
cations, subject to subparagraphs (B) and (C). 
With respect to such adjustment— 
‘‘(i) such adjustment shall be deter-
mined by the Secretary based on a weight-
ed average of the change in the total num-
ber of animal drug applications, supple-
mental animal drug applications for which 
data with respect to safety or effectiveness 
are required, manufacturing supplemental 
animal drug applications, investigational 
animal drug study submissions, and inves-
tigational animal drug protocol submis-
sions submitted to the Secretary; and 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
‘‘(ii) the Secretary shall publish in the 
Federal Register the fees resulting from 
such adjustment and the supporting meth-
odologies. 
‘‘(B) REDUCTION
OF
WORKLOAD-BASED 
INCREASE
BY
AMOUNT
OF
CERTAIN
EXCESS 
COLLECTIONS.—For each of fiscal years 2021 
through 2023, if application of the workload ad-
justment under subparagraph (A) increases the 
fee revenue amounts otherwise established for 
the fiscal year under subsection (b), as adjusted 
for inflation under paragraph (2), such fee rev-
enue increase shall be reduced by the amount of 
any excess collections, as described in sub-
section (g)(4), for the second preceding fiscal 
year, up to the amount of such fee revenue in-
crease. 
‘‘(C) RULE OF APPLICATION.—Under no 
circumstances shall the workload adjustments 
under this paragraph result in fee revenues for 
a fiscal year that are less than the fee revenues 
for that fiscal year established under subsection 
(b), as adjusted for inflation under paragraph 
(2).’’. 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
(3) 
FINAL
YEAR
ADJUSTMENT.—Section 
740(c)(4) (21 U.S.C. 379j–12(c)(4)) is amended— 
(A) by striking ‘‘2018’’ each place it ap-
pears and inserting ‘‘2023’’; and 
(B) by striking ‘‘2019’’ and inserting 
‘‘2024’’. 
(c) EXEMPTIONS FROM FEES.—Section 740(d) (21 
U.S.C. 379j–12(d)) is amended— 
(1) in the subsection heading, by inserting ‘‘; 
EXEMPTIONS FROM FEES’’ after ‘‘REDUCTION’’; 
(2) by striking the heading of paragraph (1) 
and inserting ‘‘WAIVER OR REDUCTION’’; and 
(3) by adding at the end the following: 
‘‘(4) EXEMPTIONS FROM FEES.— 
‘‘(A) CERTAIN
LABELING
SUPPLEMENTS 
TO
ADD
NUMBER
OF
APPROVED
APPLICA-
TION.—Fees under this section shall not apply 
with respect to any person who— 
‘‘(i) not later than September 30, 
2023, submits a supplemental animal drug 
application relating to a new animal drug 
application approved under section 512, 
solely to add the new animal drug applica-
tion number to the labeling of the drug in 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
the manner specified in section 502(w)(3); 
and 
‘‘(ii) otherwise would be subject to 
fees under this section solely on the basis 
of such supplemental application. 
‘‘(B) CERTAIN
ANIMAL
DRUG
APPLICA-
TIONS.—Fees under paragraphs (2), (3), and 
(4) of subsection (a) shall not apply with re-
spect to any person who is the named applicant 
or sponsor of an animal drug application, sup-
plemental animal drug application, or investiga-
tional animal drug submission if such applica-
tion or submission involves the intentional 
genomic alteration of an animal that is in-
tended to produce a drug, device, or biological 
product subject to fees under section 736, 738, 
744B, or 744H.’’. 
(d) CREDITING AND AVAILABILITY OF FEES.— 
(1) AUTHORIZATION
OF
APPROPRIATIONS.— 
Section 740(g)(3) (21 U.S.C. 379j–12(g)(3)) is 
amended— 
(A) by striking ‘‘2014 through 2018’’ and 
inserting ‘‘2019 through 2023’’; 
(B) by striking ‘‘determined’’ and inserting 
‘‘established’’; and 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
for a fiscal year under subparagraph (A) 
by the amount of any excess collections 
under this section for preceding fiscal 
years (after fiscal year 2018). 
‘‘(ii) 
WORKLOAD-BASED
FEE
AC-
COUNTING.—In applying clause (i), the 
Secretary shall account for the reduction of 
workload-based fee revenue increases by 
excess 
collections 
under 
subsection 
(c)(3)(B), in such manner as needed to 
provide that no portion of any excess col-
lections described in clause (i) is applied 
for purposes of reducing fee increases 
under both such subsection (c)(3)(B) and 
this paragraph. 
‘‘(C) RULE OF APPLICATION.—Under no 
circumstances shall adjustments under this 
paragraph result in fee revenues for a fiscal 
year that are less than the fee revenues for that 
fiscal year established in subsection (b), as ad-
justed or otherwise affected under subsection 
(c).’’. 
SEC. 104. REAUTHORIZATION; REPORTING REQUIREMENTS. 
Section 740A (21 U.S.C. 379j–13) is amended— 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
(1) in subsection (a), by striking ‘‘2013’’ and 
inserting ‘‘2018’’; 
(2) by striking ‘‘2014’’ each place it appears in 
subsections (a) and (b) and inserting ‘‘2019’’; and 
(3) in subsection (d), by striking ‘‘2018’’ each 
place it appears and inserting ‘‘2023’’. 
SEC. 105. SAVINGS CLAUSE. 
Notwithstanding the amendments made by this title, 
part 4 of subchapter C of chapter VII of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 379j–11 et seq.), as 
in effect on the day before the date of enactment of this 
title, shall continue to be in effect with respect to animal 
drug applications and supplemental animal drug applica-
tions (as defined in such part as of such day) that on or 
after October 1, 2013, but before October 1, 2018, were 
accepted by the Food and Drug Administration for filing 
with respect to assessing and collecting any fee required 
by such part for a fiscal year prior to fiscal year 2019. 
SEC. 106. EFFECTIVE DATE. 
The amendments made by this title shall take effect 
on October 1, 2018, or the date of the enactment of this 
Act, whichever is later, except that fees under part 4 of 
subchapter C of chapter VII of the Federal Food, Drug, 
and Cosmetic Act, as amended by this title, shall be as-
sessed for animal drug applications and supplemental ani-
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
mal drug applications received on or after October 1, 
2018, regardless of the date of the enactment of this Act. 
SEC. 107. SUNSET DATES. 
(a) AUTHORIZATION.—Section 740 of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 379j–12) shall 
cease to be effective October 1, 2023. 
(b) REPORTING REQUIREMENTS.—Section 740A of 
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
379j–13) shall cease to be effective January 31, 2024. 
(c) PREVIOUS SUNSET PROVISION.—Effective Octo-
ber 1, 2018, subsections (a) and (b) of section 107 of the 
Animal Drug User Fee Amendments of 2013 (Public Law 
113–14) are repealed. 
TITLE II—FEES RELATING TO 
GENERIC ANIMAL DRUGS 
SEC. 201. SHORT TITLE; FINDING. 
(a) SHORT TITLE.—This title may be cited as the 
‘‘Animal Generic Drug User Fee Amendments of 2018’’. 
(b) FINDING.—Congress finds that the fees author-
ized by the amendments made in this title will be dedi-
cated toward expediting the generic new animal drug de-
velopment process and the review of abbreviated applica-
tions for generic new animal drugs, supplemental abbre-
viated applications for generic new animal drugs, and in-
vestigational submissions for generic new animal drugs as 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
set forth in the goals identified for purposes of part 5 of 
subchapter C of chapter VII of the Federal Food, Drug, 
and Cosmetic Act, in the letters from the Secretary of 
Health and Human Services to the Chairman of the Com-
mittee on Energy and Commerce of the House of Rep-
resentatives and the Chairman of the Committee on 
Health, Education, Labor and Pensions of the Senate as 
set forth in the Congressional Record. 
SEC. 202. AUTHORITY TO ASSESS AND USE GENERIC NEW 
ANIMAL DRUG FEES. 
(a) FEE REVENUE AMOUNTS.—Subsection (b) of sec-
tion 741 (21 U.S.C. 379j–21) is amended to read as fol-
lows: 
‘‘(b) FEE REVENUE AMOUNTS.— 
‘‘(1) IN GENERAL.—Subject to subsections (c), 
(d), (f), and (g), for each of fiscal years 2019 
through 2023, the fees required under subsection (a) 
shall be established to generate a total revenue 
amount of $18,336,340. 
‘‘(2) TYPES
OF
FEES.—Of the total revenue 
amount established for a fiscal year under para-
graph (1)— 
‘‘(A) 25 percent shall be derived from fees 
under subsection (a)(1) (relating to abbreviated 
applications for a generic new animal drug); 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
‘‘(B) 37.5 percent shall be derived from 
fees under subsection (a)(2) (relating to generic 
new animal drug products); and 
‘‘(C) 37.5 percent shall be derived from 
fees under subsection (a)(3) (relating to generic 
new animal drug sponsors).’’. 
(b) ANNUAL FEE SETTING; ADJUSTMENTS.— 
(1) INFLATION ADJUSTMENT.—Section 741(c) 
(21 U.S.C. 379j–21(c)) is amended— 
(A) 
by 
redesignating 
paragraphs 
(2) 
through (4) as paragraphs (3) through (5), re-
spectively; and 
(B) by inserting after paragraph (1) the 
following: 
‘‘(2) INFLATION ADJUSTMENT.— 
‘‘(A) IN GENERAL.—For fiscal year 2020 
and subsequent fiscal years, the revenue 
amounts established under subsection (b) shall 
be adjusted by the Secretary by notice, pub-
lished in the Federal Register, for a fiscal year, 
by multiplying such revenue amounts by an 
amount equal to the sum of— 
‘‘(i) one; 
‘‘(ii) the average annual percent 
change in the cost, per full-time equivalent 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
position of the Food and Drug Administra-
tion, of all personnel compensation and 
benefits paid with respect to such positions 
for the first three of the preceding 4 fiscal 
years for which data are available, multi-
plied by the average proportion of per-
sonnel compensation and benefits costs to 
total Food and Drug Administration costs 
for the first three of the preceding 4 fiscal 
years for which data are available; and 
‘‘(iii) the average annual percent 
change that occurred in the Consumer 
Price Index for urban consumers (Wash-
ington-Baltimore, DC–MD–VA–WV; not 
seasonally adjusted; all items less food and 
energy; annual index) for the first three of 
the preceding 4 years for which data are 
available multiplied by the average propor-
tion of all costs other than personnel com-
pensation and benefits costs to total Food 
and Drug Administration costs for the 
first three of the preceding 4 fiscal years 
for which data are available. 
‘‘(B) COMPOUNDED
BASIS.—The adjust-
ment made each fiscal year after fiscal year 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
2020 under this paragraph shall be applied on 
a compounded basis to the revenue amount cal-
culated under this paragraph for the most re-
cent previous fiscal year.’’. 
(2) WORKLOAD ADJUSTMENTS.—Paragraph (3) 
of section 741(c) (21 U.S.C. 379j–21(c)), as redesig-
nated, is amended to read as follows: 
‘‘(3) WORKLOAD ADJUSTMENTS.— 
‘‘(A) IN GENERAL.—For fiscal year 2020 
and subsequent fiscal years, after the fee rev-
enue amounts established under subsection (b) 
are adjusted for inflation in accordance with 
paragraph (2), the fee revenue amounts shall be 
further adjusted for each such fiscal year to re-
flect changes in the workload of the Secretary 
for the process for the review of abbreviated ap-
plications for generic new animal drugs, subject 
to subparagraphs (B) and (C). With respect to 
such adjustment— 
‘‘(i) this adjustment shall be deter-
mined by the Secretary based on a weight-
ed average of the change in the total num-
ber of abbreviated applications for generic 
new animal drugs, manufacturing supple-
mental abbreviated applications for generic 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
new animal drugs, investigational generic 
new animal drug study submissions, and 
investigational generic new animal drug 
protocol submissions submitted to the Sec-
retary; and 
‘‘(ii) the Secretary shall publish in the 
Federal Register the fees resulting from 
this adjustment and the supporting meth-
odologies. 
‘‘(B) REDUCTION
OF
WORKLOAD-BASED 
INCREASE
BY
AMOUNT
OF
CERTAIN
EXCESS 
COLLECTIONS.—For each of fiscal years 2021 
through 2023, if application of the workload ad-
justment under subparagraph (A) increases the 
fee revenue amounts otherwise established for 
the fiscal year under subsection (b), as adjusted 
for inflation under paragraph (2), such fee rev-
enue increase shall be reduced by the amount of 
any excess collections, as described in sub-
section (g)(4), for the second preceding fiscal 
year, up to the amount of such fee revenue in-
crease. 
‘‘(C) RULE OF APPLICATION.—Under no 
circumstances 
shall 
workload 
adjustments 
under this paragraph result in fee revenues for 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
a fiscal year that are less than the fee revenues 
for that fiscal year established under subsection 
(b), as adjusted for inflation under paragraph 
(2).’’. 
(3) FINAL YEAR ADJUSTMENT.—Paragraph (4) 
of section 741(c) (21 U.S.C. 379j–21(c)), as redesig-
nated, is amended by— 
(A) striking ‘‘2018’’ each place it appears 
and inserting ‘‘2023’’; and 
(B) striking ‘‘2019’’ and inserting ‘‘2024’’. 
(c) FEE WAIVER OR REDUCTION; EXEMPTION FROM 
FEES.—Subsection (d) of section 741 (21 U.S.C. 379j– 
21) is amended to read as follows: 
‘‘(d) FEE WAIVER
OR REDUCTION; EXEMPTION 
FROM FEES.— 
‘‘(1) FEE WAIVER OR REDUCTION.—The Sec-
retary shall grant a waiver from or a reduction of 
one or more fees assessed under subsection (a) 
where the Secretary finds that the generic new ani-
mal drug is intended solely to provide for a minor 
use or minor species indication. 
‘‘(2) EXEMPTION FROM FEES.—Fees under this 
section shall not apply with respect to any person 
who— 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
‘‘(A) not later than September 30, 2023, 
submits a supplemental abbreviated application 
for a generic new animal drug approved under 
section 512, solely to add the application num-
ber to the labeling of the drug in the manner 
specified in section 502(w)(3); and 
‘‘(B) otherwise would be subject to fees 
under this section solely on the basis of such 
supplemental abbreviated application.’’. 
(d) CREDITING AND AVAILABILITY OF FEES.—Sec-
tion 741(g) (21 U.S.C. 379j–21) is amended by striking 
paragraph (3) and inserting the following paragraphs: 
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
For each of the fiscal years 2019 through 2023, 
there is authorized to be appropriated for fees under 
this section an amount equal to the total revenue 
amount established under subsection (b) for the fis-
cal year, as adjusted or otherwise affected under 
subsection (c). 
‘‘(4) EXCESS COLLECTIONS.—If the sum total 
of fees collected under this section for a fiscal year 
exceeds the amount of fees authorized to be appro-
priated for such year under paragraph (3), the ex-
cess collections shall be credited to the appropria-
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
tions account of the Food and Drug Administration 
as described in paragraph (1).’’. 
SEC. 203. REAUTHORIZATION; REPORTING REQUIREMENTS. 
Section 742 (21 U.S.C. 379j–22) is amended— 
(1) in subsection (a), by striking ‘‘2013’’ and 
inserting ‘‘2018’’; 
(2) in subsection (b), by striking ‘‘Committee 
on Health, Education, Labor, and Pensions’’ and in-
serting ‘‘the Committee on Health, Education, 
Labor and Pensions’’; 
(3) by striking ‘‘2014’’ each place it appears in 
subsections (a) and (b) and inserting ‘‘2019’’; and 
(4) in subsection (d), by striking ‘‘2018’’ each 
place it appears and inserting ‘‘2023’’. 
SEC. 204. SAVINGS CLAUSE. 
Notwithstanding the amendments made by this title, 
part 5 of subchapter C of chapter VII of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 379j–21 et seq.), as 
in effect on the day before the date of enactment of this 
title, shall continue to be in effect with respect to abbre-
viated applications for a generic new animal drug and sup-
plemental abbreviated applications for a generic new ani-
mal drug (as defined in such part as of such day) that 
on or after October 1, 2013, but before October 1, 2018, 
were accepted by the Food and Drug Administration for 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
filing with respect to assessing and collecting any fee re-
quired by such part for a fiscal year prior to fiscal year 
2019. 
SEC. 205. EFFECTIVE DATE. 
The amendments made by this title shall take effect 
on October 1, 2018, or the date of the enactment of this 
Act, whichever is later, except that fees under part 5 of 
subchapter C of chapter VII of the Federal Food, Drug, 
and Cosmetic Act, as amended by this title, shall be as-
sessed for abbreviated applications for a generic new ani-
mal drug and supplemental abbreviated applications for 
a generic new animal drug received on or after October 
1, 2018, regardless of the date of enactment of this Act. 
SEC. 206. SUNSET DATES. 
(a) AUTHORIZATION.—Section 741 of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 379j–21) shall 
cease to be effective October 1, 2023. 
(b) REPORTING REQUIREMENTS.—Section 742 of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j– 
22) shall cease to be effective January 31, 2024. 
(c) PREVIOUS SUNSET PROVISION.—Effective Octo-
ber 1, 2018, subsections (a) and (b) of section 206 of the 
Animal Generic Drug User Fee Amendments of 2013 
(Public Law 113–14) are repealed. 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
‘‘(1) ‘LEGAL STATUS—In order to be legally 
marketed, a new animal drug intended for a minor 
species must be Approved, Conditionally Approved, 
or Indexed by the Food and Drug Administration. 
THIS PRODUCT IS INDEXED—MIF.’ (followed 
by the applicable minor species index file number 
and a period) ‘Extra-label use is prohibited.’;’’; and 
(2) in paragraph (2), by striking ‘‘other ani-
mals’’ and inserting ‘‘food-producing animals’’. 
SEC. 303. MISBRANDED DRUGS AND DEVICES. 
(a) IN
GENERAL.—Section 502(w) (21 U.S.C. 
352(w)) is amended— 
(1) in subparagraph (1), by striking ‘‘; or’’ and 
inserting ‘‘;’’; 
(2) in subparagraph (2), by striking the period 
and inserting ‘‘; or’’; and 
(3) by adding at the end the following: 
‘‘(3) for which an application has been ap-
proved under section 512 and the labeling of such 
drug does not include the application number in the 
format: ‘Approved by FDA under (A)NADA # xxx– 
xxx’, except that this subparagraph shall not apply 
to representative labeling required under section 
514.1(b)(3)(v)(b) of title 21, Code of Federal Regu-
VerDate Sep 11 2014 
21:36 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00025
Fmt 6652
Sfmt 6201
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS
lations (or any successor regulation) for animal feed 
bearing or containing a new animal drug.’’. 
(b) APPLICABILITY.—Section 502(w)(3) of the Fed-
eral Food, Drug, and Cosmetic Act, as added by sub-
section (a), shall apply beginning on September 30, 2023. 
Æ 
VerDate Sep 11 2014 
20:45 Apr 23, 2018
Jkt 079200
PO 00000
Frm 00026
Fmt 6652
Sfmt 6301
E:\BILLS\H5554.IH
H5554
sradovich on DSK3GMQ082PROD with BILLS